Imugene's presenting at The American Association for Cancer Research (AACR) Annual Meeting 2024 on 9 April. Clinical trial abstracts are embargoed until the start of the conference on 5 Apr, unless selected for the official press program whereby no early abstract reveal occurs. The company's abstract is focused on the Vaxinia MAST trial, so hopefully we learn significantly more about the 38 patients enrolled to Jan 19 (up to cohort 5).
Surely this will be the catalyst for a refreshing company valuation.
DYOR, GLTAH
Imugene's presenting at The American Association for Cancer...
-
- There are more pages in this discussion • 2,100 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
-0.002(3.77%) |
Mkt cap ! $373.3M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.2¢ | 5.0¢ | $669.7K | 13.07M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1074997 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 1209633 | 6 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |